Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 76

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 2
Chunk 76
---
4  
    ($)  
    % 
  
    Operating expenses: 

    Research and development 
    $2,167,114  
    $1,713,973  
    $453,141  
     26.4%
  
    General and administrative 
     2,289,649  
     2,394,912  
     (105,263) 
     (4.4)%

    Total operating expenses 
     4,456,763  
     4,108,885  
     347,878  
     8.5%

    Loss from operations 
     (4,456,763) 
     (4,108,885) 
     (347,878) 
     8.5%

    Other income, net 
     15,547  
     93,618  
     (78,071) 
     (83.4)%
  
    Change in fair value of convertible promissory notes 
     (787,703) 
     -  
     (787,703) 
     - 

    Net loss 
    $(5,228,919) 
    $(4,015,267) 
    $(1,213,652) 
     30.2%
  
    Net loss attributable to common stockholders per share, basic and diluted 
    $(9.09) 
    $(13.16) 
    $4.07  
     (30.9)%
  
    Weighted average number of shares used in calculating net loss per share, basic and diluted 
     574,923  
     305,140  

Research
and Development Expenses

Research
and development expenses were approximately $2.2 million for the three months ended June 30, 2025, compared to approximately $1.7 million
for the three months ended June 30, 2024, representing an increase of approximately $0.5 million, or 26.4%. The increase was primarily
driven by higher clinical trial costs of approximately $0.8 million related to our ongoing Phase 1 study. This increase was partially
offset by a decrease of approximately $0.3 million in payroll and related expenses.

General
and Administrative Expenses

General
and administrative expenses were approximately $2.3 million for the three months ended June 30, 2025, compared to